Literature DB >> 18663367

The dystrobrevin-binding protein 1 gene: features and networks.

A Y Guo1, J Sun, B P Riley, D L Thiselton, K S Kendler, Z Zhao.   

Abstract

The dystrobrevin-binding protein 1 (DTNBP1) gene has been one of the most studied and promising schizophrenia susceptibility genes since it was first reported to be associated with schizophrenia in the Irish Study of High Density Schizophrenia Families (ISHDSF). Although many studies have been performed both at the functional level and in association with psychiatric disorders, there has been no systematic review of the features of the DTNBP1 gene, protein or the relationship between function and phenotype. Using a bioinformatics approach, we identified the DTNBP1 gene in 13 vertebrate species. The comparison of these genes revealed a conserved gene structure, protein-coding sequence and dysbindin domain, but a diverse noncoding sequence. The molecular evolutionary analysis suggests the DTNBP1 gene probably originated in chordates and matured in vertebrates. No signature of recent positive selection was seen in any primate lineage. The DTNBP1 gene likely has many more alternative transcripts than the current three major isoforms annotated in the NCBI database. Our examination of risk haplotypes revealed that, although the frequency of a single nucleotide polymorphism (SNP) or haplotype might be significantly different in cases from controls, difference between major geographic populations was even larger. Finally, we constructed the first DTNBP1 interactome and explored its network features. Besides the biogenesis of lysosome-related organelles complex 1 and dystrophin-associated protein complex, several molecules in the DTNBP1 network likely provide insight into the role of DTNBP1 in biological systems: retinoic acid, beta-estradiol, calmodulin and tumour necrosis factor. Studies of these subnetworks and pathways may provide opportunities to deepen our understanding of the mechanisms of action of DTNBP1 variants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663367      PMCID: PMC2859304          DOI: 10.1038/mp.2008.88

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  63 in total

1.  Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.

Authors:  Nicole C Allen; Sachin Bagade; Matthew B McQueen; John P A Ioannidis; Fotini K Kavvoura; Muin J Khoury; Rudolph E Tanzi; Lars Bertram
Journal:  Nat Genet       Date:  2008-07       Impact factor: 38.330

2.  Candidate genes for schizophrenia: a survey of association studies and gene ranking.

Authors:  Jingchun Sun; Po-Hsiu Kuo; Brien P Riley; Kenneth S Kendler; Zhongming Zhao
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

3.  Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain.

Authors:  M A Benson; S E Newey; E Martin-Rendon; R Hawkes; D J Blake
Journal:  J Biol Chem       Date:  2001-04-20       Impact factor: 5.157

4.  Analysis of high-resolution HapMap of DTNBP1 (Dysbindin) suggests no consistency between reported common variant associations and schizophrenia.

Authors:  Mousumi Mutsuddi; Derek W Morris; Skye G Waggoner; Mark J Daly; Edward M Scolnick; Pamela Sklar
Journal:  Am J Hum Genet       Date:  2006-10-03       Impact factor: 11.025

5.  Human p53 tumor suppressor gene (TP53) and schizophrenia: case-control and family studies.

Authors:  Xingqun Ni; Joseph Trakalo; Jose Valente; Maria H Azevedo; Michelle T Pato; Carlos N Pato; James L Kennedy
Journal:  Neurosci Lett       Date:  2005-11-18       Impact factor: 3.046

6.  AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families.

Authors:  Dawn L Thiselton; Vladimir I Vladimirov; Po-Hsiu Kuo; Joseph McClay; Brandon Wormley; Ayman Fanous; Francis A O'Neill; Dermot Walsh; Edwin J C G Van den Oord; Kenneth S Kendler; Brien P Riley
Journal:  Biol Psychiatry       Date:  2007-09-06       Impact factor: 13.382

7.  Estrogen directly induces expression of retinoic acid biosynthetic enzymes, compartmentalized between the epithelium and underlying stromal cells in rat uterus.

Authors:  Xiao-Hong Li; Bharati Kakkad; David E Ong
Journal:  Endocrinology       Date:  2004-06-17       Impact factor: 4.736

8.  Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia.

Authors:  Konrad Talbot; Wess L Eidem; Caroline L Tinsley; Matthew A Benson; Edward W Thompson; Rachel J Smith; Chang-Gyu Hahn; Steven J Siegel; John Q Trojanowski; Raquel E Gur; Derek J Blake; Steven E Arnold
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 9.  The molecular genetics of schizophrenia: new findings promise new insights.

Authors:  M J Owen; N M Williams; M C O'Donovan
Journal:  Mol Psychiatry       Date:  2004-01       Impact factor: 15.992

Review 10.  Schizophrenia-an evolutionary enigma?

Authors:  Martin Brüne
Journal:  Neurosci Biobehav Rev       Date:  2004-03       Impact factor: 8.989

View more
  59 in total

Review 1.  Cell biology of the BLOC-1 complex subunit dysbindin, a schizophrenia susceptibility gene.

Authors:  Ariana P Mullin; Avanti Gokhale; Jennifer Larimore; Victor Faundez
Journal:  Mol Neurobiol       Date:  2011-04-26       Impact factor: 5.590

2.  Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling.

Authors:  Daniel K Putnam; Jingchun Sun; Zhongming Zhao
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

3.  Reduced occipital and prefrontal brain volumes in dysbindin-associated schizophrenia.

Authors:  Gary Donohoe; Thomas Frodl; Derek Morris; Ilaria Spoletini; Dara M Cannon; Andrea Cherubini; Carlo Caltagirone; Paola Bossù; Colm McDonald; Michael Gill; Aiden P Corvin; Gianfranco Spalletta
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

4.  Genetic modifiers of abnormal organelle biogenesis in a Drosophila model of BLOC-1 deficiency.

Authors:  Verónica T Cheli; Richard W Daniels; Ruth Godoy; Diego J Hoyle; Vasundhara Kandachar; Marta Starcevic; Julian A Martinez-Agosto; Stephen Poole; Aaron DiAntonio; Vett K Lloyd; Henry C Chang; David E Krantz; Esteban C Dell'Angelica
Journal:  Hum Mol Genet       Date:  2009-12-16       Impact factor: 6.150

5.  A multi-dimensional evidence-based candidate gene prioritization approach for complex diseases-schizophrenia as a case.

Authors:  Jingchun Sun; Peilin Jia; Ayman H Fanous; Bradley T Webb; Edwin J C G van den Oord; Xiangning Chen; Jozsef Bukszar; Kenneth S Kendler; Zhongming Zhao
Journal:  Bioinformatics       Date:  2009-07-14       Impact factor: 6.937

6.  Schizophrenia gene networks and pathways and their applications for novel candidate gene selection.

Authors:  Jingchun Sun; Peilin Jia; Ayman H Fanous; Edwin van den Oord; Xiangning Chen; Brien P Riley; Richard L Amdur; Kenneth S Kendler; Zhongming Zhao
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

7.  A comparative study of cancer proteins in the human protein-protein interaction network.

Authors:  Jingchun Sun; Zhongming Zhao
Journal:  BMC Genomics       Date:  2010-12-01       Impact factor: 3.969

8.  Schizophrenia genomics and proteomics: are we any closer to biomarker discovery?

Authors:  Shaheen E Lakhan; Alon Kramer
Journal:  Behav Brain Funct       Date:  2009-01-07       Impact factor: 3.759

9.  Schizophrenia pathophysiology: are we any closer to a complete model?

Authors:  Shaheen E Lakhan; Karen F Vieira
Journal:  Ann Gen Psychiatry       Date:  2009-05-15       Impact factor: 3.455

10.  The dysbindin-containing complex (BLOC-1) in brain: developmental regulation, interaction with SNARE proteins and role in neurite outgrowth.

Authors:  C A Ghiani; M Starcevic; I A Rodriguez-Fernandez; R Nazarian; V T Cheli; L N Chan; J S Malvar; J de Vellis; C Sabatti; E C Dell'Angelica
Journal:  Mol Psychiatry       Date:  2009-06-23       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.